Akin Gump Advises Nantahala Capital in Soleno Investment

January 17, 2023

Reading Time : 1 min

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Sarah Richmond

Senior Communications Manager

(New York) – Akin Gump represented Nantahala Capital Management in its securities purchase agreement, alongside co-investors Abingworth LLP and Vivo Capital, LLC, for up to $60 million, with Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases.

Under the terms of the agreement, the investors have committed to pay $10 million in exchange for warrants to purchase common stock upon the company’s announcement of enrollment completion in the randomized withdrawal period of Study C602, anticipated in the first quarter of 2023.

To learn more, click here.

The deal team was led by corporate partner Shar Ahmed and senior counsel Alexandra Reuss.

Akin Gump Strauss Hauer & Feld LLP is a leading international law firm with more than 900 lawyers in offices throughout the United States, Europe, Asia and the Middle East.

###

Share This Insight

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.